Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice
Oxidative stress has been implicated in vascular injury and atherogenesis, and antioxidant treatment has shown favorable results in preclinical studies. Despite this, antioxidant therapy has failed to show benefit in clinical trials. Failure of antioxidants in clinical trials may be partly because s...
Gespeichert in:
Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2004-05, Vol.109 (20), p.2448-2453 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2453 |
---|---|
container_issue | 20 |
container_start_page | 2448 |
container_title | Circulation (New York, N.Y.) |
container_volume | 109 |
creator | CHYU, Kuang-Yuh BABBIDGE, Stephanie M XIAONING ZHAO DANDILLAYA, Ram RIETVELD, Anton G YANO, Juliana DIMAYUGA, Paul CERCEK, Bojan SHAH, Prediman K |
description | Oxidative stress has been implicated in vascular injury and atherogenesis, and antioxidant treatment has shown favorable results in preclinical studies. Despite this, antioxidant therapy has failed to show benefit in clinical trials. Failure of antioxidants in clinical trials may be partly because such therapy is started after atherosclerosis is already well established, whereas the benefits in animal models may be results from early initiation of antioxidants while atherosclerosis is still evolving.
To test this hypothesis, we evaluated the effect of epigallocatechin gallate (EGCG), the main antioxidant derived from green tea, on evolving and established atherosclerotic lesions in hypercholesterolemic apolipoprotein E-null mice. Established native aortic atherosclerotic lesions and evolving atherosclerotic lesions produced by periadventitial cuff injury to carotid arteries were assessed in mice after 21 and 42 days of treatment with daily intraperitoneal injections of EGCG (10 mg/kg) or PBS. EGCG treatment resulted in an increase in the antioxidant capacity in local vascular tissue and systemic circulation and reduced vascular smooth muscle cell proliferation and redox-sensitive gene activation in vitro. EGCG reduced cuff-induced evolving atherosclerotic plaque size at 21 and 42 days by 55% and 73%, respectively, compared with PBS treatment (P |
doi_str_mv | 10.1161/01.cir.0000128034.70732.c2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71948576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71948576</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-ae37a6b0e8ab74f309c83896e3ed3be4e8779892dec74293f92aa082e3aa1d303</originalsourceid><addsrcrecordid>eNpFkU9r3DAQxUVoSDabfIUiCu3Njv7YktVb2SZtIBAo7VmM5XFWRWu7kr2QY795tMnC6jDSoN_TPPQI-cRZybnit4yXzseS5cVFw2RVaqalKJ04Iytei6qoamk-kFUGTJFvxCW5SulvbpXU9QW55DWXqmZsRf5_932PEYfZQ6CYz25OdOzpc0Qc6IxQdBj9HjvqYEa39QMdB9rhHsM4-eGZ7jGmJVFMM7TBp20mYd5iHJMLh-oTzRqYxuCncYrjjLm9K4YlBLrzDq_JeQ8h4c1xX5M_93e_Nz-Lx6cfD5tvj4WrmZoLQKlBtQwbaHXVS2ZcIxujUGInW6yw0do0RnTodCWM7I0AYI1ACcA7yeSafHl_N3v4t2S7dueTwxBgwHFJVnNTNbVWGfz6DrrsPkXs7RT9DuKL5cweArCM283DL3sKwL4FYDciiz8epyztDruT9PjjGfh8BCA5CH2Ewfl04pRiWteVfAWas5JF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71948576</pqid></control><display><type>article</type><title>Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><creator>CHYU, Kuang-Yuh ; BABBIDGE, Stephanie M ; XIAONING ZHAO ; DANDILLAYA, Ram ; RIETVELD, Anton G ; YANO, Juliana ; DIMAYUGA, Paul ; CERCEK, Bojan ; SHAH, Prediman K</creator><creatorcontrib>CHYU, Kuang-Yuh ; BABBIDGE, Stephanie M ; XIAONING ZHAO ; DANDILLAYA, Ram ; RIETVELD, Anton G ; YANO, Juliana ; DIMAYUGA, Paul ; CERCEK, Bojan ; SHAH, Prediman K</creatorcontrib><description>Oxidative stress has been implicated in vascular injury and atherogenesis, and antioxidant treatment has shown favorable results in preclinical studies. Despite this, antioxidant therapy has failed to show benefit in clinical trials. Failure of antioxidants in clinical trials may be partly because such therapy is started after atherosclerosis is already well established, whereas the benefits in animal models may be results from early initiation of antioxidants while atherosclerosis is still evolving.
To test this hypothesis, we evaluated the effect of epigallocatechin gallate (EGCG), the main antioxidant derived from green tea, on evolving and established atherosclerotic lesions in hypercholesterolemic apolipoprotein E-null mice. Established native aortic atherosclerotic lesions and evolving atherosclerotic lesions produced by periadventitial cuff injury to carotid arteries were assessed in mice after 21 and 42 days of treatment with daily intraperitoneal injections of EGCG (10 mg/kg) or PBS. EGCG treatment resulted in an increase in the antioxidant capacity in local vascular tissue and systemic circulation and reduced vascular smooth muscle cell proliferation and redox-sensitive gene activation in vitro. EGCG reduced cuff-induced evolving atherosclerotic plaque size at 21 and 42 days by 55% and 73%, respectively, compared with PBS treatment (P<0.05). Conversely, EGCG had no effect on established lesions in the aortic sinuses or the rest of the aorta.
Our data suggest that antioxidant EGCG differentially reduces evolving atherosclerotic lesions without influencing established atherosclerosis in the apolipoprotein E-null mice.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.cir.0000128034.70732.c2</identifier><identifier>PMID: 15136500</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Animals ; Antioxidants - analysis ; Antioxidants - therapeutic use ; Apolipoproteins E - genetics ; Arteriosclerosis - drug therapy ; Arteriosclerosis - metabolism ; Arteriosclerosis - pathology ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Camellia sinensis - chemistry ; Cardiology. Vascular system ; Cardiovascular system ; Carotid Artery Diseases - drug therapy ; Carotid Artery Diseases - pathology ; Catechin - analogs & derivatives ; Catechin - blood ; Catechin - therapeutic use ; Cell Division ; Cholesterol - blood ; Disease Progression ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Male ; Medical sciences ; Mice ; Mice, Knockout ; Muscle, Smooth, Vascular - cytology ; Muscle, Smooth, Vascular - drug effects ; Muscle, Smooth, Vascular - pathology ; Nitric Oxide Synthase - metabolism ; Nitric Oxide Synthase Type II ; Pharmacology. Drug treatments ; Transcription Factor AP-1 - metabolism ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Circulation (New York, N.Y.), 2004-05, Vol.109 (20), p.2448-2453</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-ae37a6b0e8ab74f309c83896e3ed3be4e8779892dec74293f92aa082e3aa1d303</citedby><cites>FETCH-LOGICAL-c506t-ae37a6b0e8ab74f309c83896e3ed3be4e8779892dec74293f92aa082e3aa1d303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3678,27915,27916</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16607754$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15136500$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHYU, Kuang-Yuh</creatorcontrib><creatorcontrib>BABBIDGE, Stephanie M</creatorcontrib><creatorcontrib>XIAONING ZHAO</creatorcontrib><creatorcontrib>DANDILLAYA, Ram</creatorcontrib><creatorcontrib>RIETVELD, Anton G</creatorcontrib><creatorcontrib>YANO, Juliana</creatorcontrib><creatorcontrib>DIMAYUGA, Paul</creatorcontrib><creatorcontrib>CERCEK, Bojan</creatorcontrib><creatorcontrib>SHAH, Prediman K</creatorcontrib><title>Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Oxidative stress has been implicated in vascular injury and atherogenesis, and antioxidant treatment has shown favorable results in preclinical studies. Despite this, antioxidant therapy has failed to show benefit in clinical trials. Failure of antioxidants in clinical trials may be partly because such therapy is started after atherosclerosis is already well established, whereas the benefits in animal models may be results from early initiation of antioxidants while atherosclerosis is still evolving.
To test this hypothesis, we evaluated the effect of epigallocatechin gallate (EGCG), the main antioxidant derived from green tea, on evolving and established atherosclerotic lesions in hypercholesterolemic apolipoprotein E-null mice. Established native aortic atherosclerotic lesions and evolving atherosclerotic lesions produced by periadventitial cuff injury to carotid arteries were assessed in mice after 21 and 42 days of treatment with daily intraperitoneal injections of EGCG (10 mg/kg) or PBS. EGCG treatment resulted in an increase in the antioxidant capacity in local vascular tissue and systemic circulation and reduced vascular smooth muscle cell proliferation and redox-sensitive gene activation in vitro. EGCG reduced cuff-induced evolving atherosclerotic plaque size at 21 and 42 days by 55% and 73%, respectively, compared with PBS treatment (P<0.05). Conversely, EGCG had no effect on established lesions in the aortic sinuses or the rest of the aorta.
Our data suggest that antioxidant EGCG differentially reduces evolving atherosclerotic lesions without influencing established atherosclerosis in the apolipoprotein E-null mice.</description><subject>Animals</subject><subject>Antioxidants - analysis</subject><subject>Antioxidants - therapeutic use</subject><subject>Apolipoproteins E - genetics</subject><subject>Arteriosclerosis - drug therapy</subject><subject>Arteriosclerosis - metabolism</subject><subject>Arteriosclerosis - pathology</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Camellia sinensis - chemistry</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular system</subject><subject>Carotid Artery Diseases - drug therapy</subject><subject>Carotid Artery Diseases - pathology</subject><subject>Catechin - analogs & derivatives</subject><subject>Catechin - blood</subject><subject>Catechin - therapeutic use</subject><subject>Cell Division</subject><subject>Cholesterol - blood</subject><subject>Disease Progression</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Muscle, Smooth, Vascular - cytology</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Muscle, Smooth, Vascular - pathology</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Nitric Oxide Synthase Type II</subject><subject>Pharmacology. Drug treatments</subject><subject>Transcription Factor AP-1 - metabolism</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU9r3DAQxUVoSDabfIUiCu3Njv7YktVb2SZtIBAo7VmM5XFWRWu7kr2QY795tMnC6jDSoN_TPPQI-cRZybnit4yXzseS5cVFw2RVaqalKJ04Iytei6qoamk-kFUGTJFvxCW5SulvbpXU9QW55DWXqmZsRf5_932PEYfZQ6CYz25OdOzpc0Qc6IxQdBj9HjvqYEa39QMdB9rhHsM4-eGZ7jGmJVFMM7TBp20mYd5iHJMLh-oTzRqYxuCncYrjjLm9K4YlBLrzDq_JeQ8h4c1xX5M_93e_Nz-Lx6cfD5tvj4WrmZoLQKlBtQwbaHXVS2ZcIxujUGInW6yw0do0RnTodCWM7I0AYI1ACcA7yeSafHl_N3v4t2S7dueTwxBgwHFJVnNTNbVWGfz6DrrsPkXs7RT9DuKL5cweArCM283DL3sKwL4FYDciiz8epyztDruT9PjjGfh8BCA5CH2Ewfl04pRiWteVfAWas5JF</recordid><startdate>20040525</startdate><enddate>20040525</enddate><creator>CHYU, Kuang-Yuh</creator><creator>BABBIDGE, Stephanie M</creator><creator>XIAONING ZHAO</creator><creator>DANDILLAYA, Ram</creator><creator>RIETVELD, Anton G</creator><creator>YANO, Juliana</creator><creator>DIMAYUGA, Paul</creator><creator>CERCEK, Bojan</creator><creator>SHAH, Prediman K</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040525</creationdate><title>Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice</title><author>CHYU, Kuang-Yuh ; BABBIDGE, Stephanie M ; XIAONING ZHAO ; DANDILLAYA, Ram ; RIETVELD, Anton G ; YANO, Juliana ; DIMAYUGA, Paul ; CERCEK, Bojan ; SHAH, Prediman K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-ae37a6b0e8ab74f309c83896e3ed3be4e8779892dec74293f92aa082e3aa1d303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antioxidants - analysis</topic><topic>Antioxidants - therapeutic use</topic><topic>Apolipoproteins E - genetics</topic><topic>Arteriosclerosis - drug therapy</topic><topic>Arteriosclerosis - metabolism</topic><topic>Arteriosclerosis - pathology</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Camellia sinensis - chemistry</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular system</topic><topic>Carotid Artery Diseases - drug therapy</topic><topic>Carotid Artery Diseases - pathology</topic><topic>Catechin - analogs & derivatives</topic><topic>Catechin - blood</topic><topic>Catechin - therapeutic use</topic><topic>Cell Division</topic><topic>Cholesterol - blood</topic><topic>Disease Progression</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Muscle, Smooth, Vascular - cytology</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Muscle, Smooth, Vascular - pathology</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Nitric Oxide Synthase Type II</topic><topic>Pharmacology. Drug treatments</topic><topic>Transcription Factor AP-1 - metabolism</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHYU, Kuang-Yuh</creatorcontrib><creatorcontrib>BABBIDGE, Stephanie M</creatorcontrib><creatorcontrib>XIAONING ZHAO</creatorcontrib><creatorcontrib>DANDILLAYA, Ram</creatorcontrib><creatorcontrib>RIETVELD, Anton G</creatorcontrib><creatorcontrib>YANO, Juliana</creatorcontrib><creatorcontrib>DIMAYUGA, Paul</creatorcontrib><creatorcontrib>CERCEK, Bojan</creatorcontrib><creatorcontrib>SHAH, Prediman K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHYU, Kuang-Yuh</au><au>BABBIDGE, Stephanie M</au><au>XIAONING ZHAO</au><au>DANDILLAYA, Ram</au><au>RIETVELD, Anton G</au><au>YANO, Juliana</au><au>DIMAYUGA, Paul</au><au>CERCEK, Bojan</au><au>SHAH, Prediman K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2004-05-25</date><risdate>2004</risdate><volume>109</volume><issue>20</issue><spage>2448</spage><epage>2453</epage><pages>2448-2453</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Oxidative stress has been implicated in vascular injury and atherogenesis, and antioxidant treatment has shown favorable results in preclinical studies. Despite this, antioxidant therapy has failed to show benefit in clinical trials. Failure of antioxidants in clinical trials may be partly because such therapy is started after atherosclerosis is already well established, whereas the benefits in animal models may be results from early initiation of antioxidants while atherosclerosis is still evolving.
To test this hypothesis, we evaluated the effect of epigallocatechin gallate (EGCG), the main antioxidant derived from green tea, on evolving and established atherosclerotic lesions in hypercholesterolemic apolipoprotein E-null mice. Established native aortic atherosclerotic lesions and evolving atherosclerotic lesions produced by periadventitial cuff injury to carotid arteries were assessed in mice after 21 and 42 days of treatment with daily intraperitoneal injections of EGCG (10 mg/kg) or PBS. EGCG treatment resulted in an increase in the antioxidant capacity in local vascular tissue and systemic circulation and reduced vascular smooth muscle cell proliferation and redox-sensitive gene activation in vitro. EGCG reduced cuff-induced evolving atherosclerotic plaque size at 21 and 42 days by 55% and 73%, respectively, compared with PBS treatment (P<0.05). Conversely, EGCG had no effect on established lesions in the aortic sinuses or the rest of the aorta.
Our data suggest that antioxidant EGCG differentially reduces evolving atherosclerotic lesions without influencing established atherosclerosis in the apolipoprotein E-null mice.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>15136500</pmid><doi>10.1161/01.cir.0000128034.70732.c2</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 2004-05, Vol.109 (20), p.2448-2453 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_proquest_miscellaneous_71948576 |
source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload |
subjects | Animals Antioxidants - analysis Antioxidants - therapeutic use Apolipoproteins E - genetics Arteriosclerosis - drug therapy Arteriosclerosis - metabolism Arteriosclerosis - pathology Atherosclerosis (general aspects, experimental research) Biological and medical sciences Blood and lymphatic vessels Camellia sinensis - chemistry Cardiology. Vascular system Cardiovascular system Carotid Artery Diseases - drug therapy Carotid Artery Diseases - pathology Catechin - analogs & derivatives Catechin - blood Catechin - therapeutic use Cell Division Cholesterol - blood Disease Progression Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Male Medical sciences Mice Mice, Knockout Muscle, Smooth, Vascular - cytology Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - pathology Nitric Oxide Synthase - metabolism Nitric Oxide Synthase Type II Pharmacology. Drug treatments Transcription Factor AP-1 - metabolism Vasodilator agents. Cerebral vasodilators |
title | Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T04%3A21%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20effects%20of%20green%20tea-derived%20catechin%20on%20developing%20versus%20established%20atherosclerosis%20in%20apolipoprotein%20E-null%20mice&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=CHYU,%20Kuang-Yuh&rft.date=2004-05-25&rft.volume=109&rft.issue=20&rft.spage=2448&rft.epage=2453&rft.pages=2448-2453&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.cir.0000128034.70732.c2&rft_dat=%3Cproquest_cross%3E71948576%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71948576&rft_id=info:pmid/15136500&rfr_iscdi=true |